Literature DB >> 11200963

Implications of impulsive and affective symptoms for serotonin function in bulimia nervosa.

H Steiger1, S N Young, N M Kin, N Koerner, M Israel, P Lageix, J Paris.   

Abstract

BACKGROUND: Bulimic, impulsive and depressive syndromes have all been associated with abnormalities in brain serotonin (5-hydroxytryptamine; 5-HT) mechanisms.
METHODS: We had 26 bulimic women and 22 normal-eater women report impulsive, affective, self-destructive and bulimic symptoms, and then provide serial blood samples for measurement of: [3H]-paroxetine binding in platelets; and, prolactin (PRL) responses following oral meta-chlorophenylpiperazine (m-CPP).
RESULTS: Bulimic status was associated with markedly reduced density of paroxetine-binding sites, modest blunting of m-CPP stimulated PRL response, and greater nausea following m-CPP. Biological variables did not co-vary with most psychopathological or eating-symptom indices. However, there were inverse associations (in bulimic women only) between scores indicating impulsivity (largely 'unreflectiveness') and density of platelet 5-HT uptake sites.
CONCLUSIONS: Our observations link bulimia nervosa to altered 5-HT functioning, and suggest that there may be a relatively symptom-specific association between impulsivity and reduced 5-HT reuptake.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11200963     DOI: 10.1017/s003329179900313x

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  17 in total

1.  Treatment improves serotonin transporter binding and reduces binge eating.

Authors:  Liisa I Tammela; Aila Rissanen; Jyrki T Kuikka; Leila J Karhunen; Kim A Bergström; Eila Repo-Tiihonen; Hannu Naukkarinen; Esko Vanninen; Jari Tiihonen; Matti Uusitupa
Journal:  Psychopharmacology (Berl)       Date:  2003-05-27       Impact factor: 4.530

2.  Impaired platelet [3H]paroxetine binding in female patients with borderline personality disorder.

Authors:  N M K Ng Ying Kin; Joel Paris; George Schwartz; Hallie Zweig-Frank; Howard Steiger; N P V Nair
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

3.  Impulsivity and test meal intake among women with bulimia nervosa.

Authors:  Robyn Sysko; Rachel Ojserkis; Janet Schebendach; Suzette M Evans; Tom Hildebrandt; B Timothy Walsh
Journal:  Appetite       Date:  2017-01-07       Impact factor: 3.868

Review 4.  Functional disturbances within frontostriatal circuits across multiple childhood psychopathologies.

Authors:  Rachel Marsh; Tiago V Maia; Bradley S Peterson
Journal:  Am J Psychiatry       Date:  2009-05-15       Impact factor: 18.112

Review 5.  Neurobiology of anorexia and bulimia nervosa.

Authors:  Walter Kaye
Journal:  Physiol Behav       Date:  2007-11-29

6.  Serotonin-induced decrease of intracellular Ca(2+) release in platelets of bulimic patients normalizes during treatment.

Authors:  Lars Wöckel; Florian Daniel Zepf; Sabrina Koch; Anikó-Eva Meyer-Keitel; Martin H Schmidt
Journal:  J Neural Transm (Vienna)       Date:  2008-12-10       Impact factor: 3.575

7.  Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness.

Authors:  Ursula F Bailer; Julie C Price; Carolyn C Meltzer; Chester A Mathis; Guido K Frank; Lisa Weissfeld; Claire W McConaha; Shannan E Henry; Sarah Brooks-Achenbach; Nicole C Barbarich; Walter H Kaye
Journal:  Neuropsychopharmacology       Date:  2004-06       Impact factor: 7.853

Review 8.  The role of cognitive deficits in the development of eating disorders.

Authors:  Suji M Lena; Alexandra J Fiocco; JoAnna K Leyenaar
Journal:  Neuropsychol Rev       Date:  2004-06       Impact factor: 7.444

Review 9.  Cognitive-behavioural therapy for individuals with bulimia nervosa and a co-occurring substance use disorder.

Authors:  Robyn Sysko; Tom Hildebrandt
Journal:  Eur Eat Disord Rev       Date:  2009-03

Review 10.  Pediatric obesity: parallels with addiction and treatment recommendations.

Authors:  Michelle C Acosta; Jeanne Manubay; Frances R Levin
Journal:  Harv Rev Psychiatry       Date:  2008       Impact factor: 3.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.